Table 11. References for studies on non–cisplatin chemoradiotherapy regimen (continued).
| Study, author | Arms | LRC | DC | Response | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2-yr LRC | Diff in LRC | 3-yr DC | 5-yr DC | Diff in DC | Overall Resp | Diff in Resp | ||||
| Bonner et al. (19) | A. RT alone | 41% | B>A, P=0.005 | 83% | – | None reported | 64% | B>A, P=0.02 | ||
| B. Cetux-CRT | 50% | 84% | – | 74% | ||||||
| Gillison et al. (20) | A. HDC-CRT | 90% (5-yr) | A>B, P=0.0005 | – | – | P=0.09 | – | – | ||
| B. Cetux-CRT | 83% (5-yr) | – | – | – | – | |||||
| Mehanna et al. (21) | A. HDC-CRT | 94% | A>B, P=0.0007 | 97%, ns | – | A>B, P=0.01 | – | – | ||
| B. Cetux-CRT | 84% | 91%, ns | – | – | – | |||||
| Shapiro et al. (22) | A. HDC-CRT | 94% (4-yr) | C>A, P<0.0001 | – | 88% (4-yr) | None reported | – | – | ||
| B. Carbo-CRT | 90% (4-yr) | – | 82% (4-yr) | – | – | |||||
| C. Cetux-CRT | 60 (4-yr) | – | 71% (4-yr) | – | – | |||||
| Denis et al. (23) | A. RT alone | 25% (5-yr) | B>A, P=0.002 | 83%, ns | – | None reported | – | – | ||
| B. Carbo-CRT | 48% (5-yr) | 82%, ns | – | – | – | |||||
| Tao et al., Abstract only (24) | A. HDC-CRT | – | – | – | – | – | – | – | ||
| B. Cetux/Ave-RT | – | – | – | – | – | – | – | |||
LRC, locoregional control; DC, distant control; Cis, cisplatin; CRT, chemoradiation; Diff, difference; Resp, response; RT, radiotherapy; Cetux, cetuximab; Carbo, carboplatin; HDC, high dose cisplatin; Cetux/Ave, cetuximab or avelumab.